Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1988
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 2
1992 2
1994 2
1995 4
1996 4
1997 4
1998 6
1999 18
2000 13
2001 20
2002 11
2003 17
2004 20
2005 12
2006 13
2007 7
2008 8
2009 12
2010 13
2011 15
2012 9
2013 7
2014 11
2015 11
2016 10
2017 13
2018 10
2019 6
2020 7
2021 8
2022 14
2023 12
2024 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. Vodenkova S, et al. Pharmacol Ther. 2020 Feb;206:107447. doi: 10.1016/j.pharmthera.2019.107447. Epub 2019 Nov 19. Pharmacol Ther. 2020. PMID: 31756363 Review.
Despite the encouraging progress in CRC therapy to date, the patients' response rates to therapy continue to remain low and the patients' benefit from 5-FU-based therapy is frequently compromised by the development of chemoresistance. Inter-individual differences in the tr …
Despite the encouraging progress in CRC therapy to date, the patients' response rates to therapy continue to remain low and the patie …
Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer.
Wang G, Huang Y, Zhou L, Yang H, Lin H, Zhou S, Tan Z, Qian J. Wang G, et al. Crit Rev Oncol Hematol. 2024 Jun;198:104197. doi: 10.1016/j.critrevonc.2023.104197. Epub 2023 Nov 10. Crit Rev Oncol Hematol. 2024. PMID: 37951282 Review.
For patients diagnosed with advanced gastric or gastroesophageal cancer that is not amenable to surgical intervention, the standard of care for first-line treatment consists of fluoropyrimidine and platinum-based chemotherapy. The incorporation of novel agents into these s …
For patients diagnosed with advanced gastric or gastroesophageal cancer that is not amenable to surgical intervention, the standard of care …
How we treat esophageal squamous cell carcinoma.
Puhr HC, Prager GW, Ilhan-Mutlu A. Puhr HC, et al. ESMO Open. 2023 Feb;8(1):100789. doi: 10.1016/j.esmoop.2023.100789. Epub 2023 Feb 13. ESMO Open. 2023. PMID: 36791637 Free PMC article. Review.
In the absence of pathological complete response after neoadjuvant radiochemotherapy and R0 resection, adjuvant immunotherapy for 1 year should be administered to improve disease-free survival. In metastatic first-line setting, combination of platin/fluoropyrimidine
In the absence of pathological complete response after neoadjuvant radiochemotherapy and R0 resection, adjuvant immunotherapy for 1 y …
Chemotherapy for advanced gastric cancer.
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Wagner AD, et al. Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4. Cochrane Database Syst Rev. 2017. PMID: 28850174 Free PMC article. Review.
We are uncertain whether taxane-platinum combinations with (versus without) fluoropyrimidines extend OS due to very low-quality evidence (HR 0.86, 95% CI 0.71 to 1.06, 482 participants, three studies, very low-quality evidence). ...Furthermore, docetaxel-containing three-d …
We are uncertain whether taxane-platinum combinations with (versus without) fluoropyrimidines extend OS due to very low-quality evide …
Capecitabine: a review.
Walko CM, Lindley C. Walko CM, et al. Clin Ther. 2005 Jan;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005. Clin Ther. 2005. PMID: 15763604 Review.

Single-agent capecitabine was compared with IV FU/leucovorin (LV) using the bolus Mayo Clinic regimen in 2 Phase III trials as first-line treatment for patients with metastatic colorectal cancer. Overall response rate (RR) favored the capecitabine arm (26% vs 17%, P < 0

Single-agent capecitabine was compared with IV FU/leucovorin (LV) using the bolus Mayo Clinic regimen in 2 Phase III trials as first-line tr …
Management of Rectal Cancer.
Schlechter BL. Schlechter BL. Hematol Oncol Clin North Am. 2022 Jun;36(3):521-537. doi: 10.1016/j.hoc.2022.03.002. Epub 2022 May 13. Hematol Oncol Clin North Am. 2022. PMID: 35577705 Review.
For stage II and III rectal cancer, neoadjuvant radiation, either as long-course chemoradiotherapy with a sensitizing fluoropyrimidine or short-course radiation, should be offered in all cases. Adjuvant or neoadjuvant fluoropyrimidine and oxaliplatin chemotherapy al …
For stage II and III rectal cancer, neoadjuvant radiation, either as long-course chemoradiotherapy with a sensitizing fluoropyrimidine
Capecitabine.
Dooley M, Goa KL. Dooley M, et al. Drugs. 1999 Jul;58(1):69-76; discussion 77-8. doi: 10.2165/00003495-199958010-00006. Drugs. 1999. PMID: 10439930 Review.
Capecitabine is an orally administered fluoropyrimidine carbamate used for the treatment of paclitaxel- or anthracycline-refractory breast cancer. ...In this trial, the median duration of response was 241 days. Disease progression or death occurred in 83% of patient …
Capecitabine is an orally administered fluoropyrimidine carbamate used for the treatment of paclitaxel- or anthracycline-refractory b …
Implementation of pharmacogenomics: Where are we now?
Medwid S, Kim RB. Medwid S, et al. Br J Clin Pharmacol. 2024 Aug;90(8):1763-1781. doi: 10.1111/bcp.15591. Epub 2022 Dec 16. Br J Clin Pharmacol. 2024. PMID: 36366858 Review.
Pharmacogenomics (PGx), examining the effect of genetic variation on interpatient variation in drug disposition and response, has been widely studied for several decades. However, as cost, as well as turnaround time associated with PGx testing, has significantly improved, …
Pharmacogenomics (PGx), examining the effect of genetic variation on interpatient variation in drug disposition and response, has bee …
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer.
Martínez-Pérez J, Torrado C, Domínguez-Cejudo MA, Valladares-Ayerbes M. Martínez-Pérez J, et al. Int J Mol Sci. 2024 Jun 5;25(11):6220. doi: 10.3390/ijms25116220. Int J Mol Sci. 2024. PMID: 38892410 Free PMC article. Review.
The standard of care for patients with stage III and high-risk stage II colorectal cancer (CRC) includes surgery and adjuvant chemotherapy. Fluoropyrimidines and their combination with oxaliplatin increased the cure rates, being able to eradicate the occult metastatic SC i …
The standard of care for patients with stage III and high-risk stage II colorectal cancer (CRC) includes surgery and adjuvant chemotherapy. …
Capecitabine.
Budman DR. Budman DR. Invest New Drugs. 2000 Nov;18(4):355-63. doi: 10.1023/a:1006449315650. Invest New Drugs. 2000. PMID: 11081571 Review.
This agent demonstrates significant antitumor effect in diseases known to be responsive to fluoropyrimidines. Further study is needed to determine whether capecitabine has a broader spectrum of action thus affecting other tumor types than 5-fluorouracil. ...
This agent demonstrates significant antitumor effect in diseases known to be responsive to fluoropyrimidines. Further study is …
309 results